Sign In

Login

Password

Forgot Password ? Sign Up

標的化ドラッグデリバリー (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "標的化ドラッグデリバリー" in Japanese language version.

refsWebsite
Global rank Japanese rank
16nih.gov
4th place
24th place
15doi.org
2nd place
6th place
2worldcat.org
5th place
19th place
1accessscience.com
low place
low place
1web.archive.org
1st place
1st place
1umn.edu
1,266th place
4,821st place
1medscape.com
719th place
3,311th place

accessscience.com

  • Saltzman (2008年). “Drug delivery systems”. AccessScience. McGraw-Hill Companies. 2021年1月17日閲覧。

doi.org

  • Muller, R; Keck, C (2004). “Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles”. Journal of Biotechnology 113 (1–3): 151–170. doi:10.1016/j.jbiotec.2004.06.007. PMID 15380654. 
  • Bertrand N, Leroux JC.; Leroux (2011). “The journey of a drug carrier in the body: an anatomo-physiological perspective”. Journal of Controlled Release 161 (2): 152–63. doi:10.1016/j.jconrel.2011.09.098. PMID 22001607. 
  • Scott, Robert C; Crabbe, Deborah; Krynska, Barbara; Ansari, Ramin; Kiani, Mohammad F (2008). “Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue”. Expert Opinion on Drug Delivery 5 (4): 459–70. doi:10.1517/17425247.5.4.459. PMID 18426386. 
  • Noyhouzer, Tomer; L’Homme, Chloé; Beaulieu, Isabelle; Mazurkiewicz, Stephanie; Kuss, Sabine; Kraatz, Heinz-Bernhard; Canesi, Sylvain; Mauzeroll, Janine (2016-05-03). “Ferrocene-Modified Phospholipid: An Innovative Precursor for Redox-Triggered Drug Delivery Vesicles Selective to Cancer Cells”. Langmuir 32 (17): 4169–4178. doi:10.1021/acs.langmuir.6b00511. ISSN 0743-7463. PMID 26987014. 
  • He, X; Bonaparte, N; Kim, S; Acharya, B; Lee, JY; Chi, L; Lee, HJ; Paik, YK et al. (2012). “Enhanced delivery of T cells to tumor after chemotherapy using membrane-anchored, apoptosis-targeted peptide”. Journal of Controlled Release 162 (6): 521–8. doi:10.1016/j.jconrel.2012.07.023. PMID 22824781. 
  • Cobleigh, M; Langmuir, VK; Sledge, GW; Miller, KD; Haney, L; Novotny, WF; Reimann, JD; Vassel, A (2003). “A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer”. Seminars in Oncology 30 (5 Suppl 16): 117–24. doi:10.1053/j.seminoncol.2003.08.013. PMID 14613032. 
  • Seidman, A.; Hudis, C; Pierri, MK; Shak, S; Paton, V; Ashby, M; Murphy, M; Stewart, SJ et al. (2002). “Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience”. Journal of Clinical Oncology 20 (5): 1215–21. doi:10.1200/JCO.20.5.1215. PMID 11870163. 
  • Brufsky, Adam (2009). “Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer”. American Journal of Clinical Oncology 33 (2): 186–95. doi:10.1097/COC.0b013e318191bfb0. PMID 19675448. 
  • Lee, Jinhyun Hannah; Yeo, Yoon (2015-03-24). “Controlled drug release from pharmaceutical nanocarriers”. Chemical Engineering Science 125: 75–84. doi:10.1016/j.ces.2014.08.046. PMC 4322773. PMID 25684779. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322773/. 
  • Cho, Kwangjae; Wang, Xu; Nie, Shuming; Chen, Zhuo Georgia; Shin, Dong M. (2008-03-01). “Therapeutic nanoparticles for drug delivery in cancer”. Clinical Cancer Research 14 (5): 1310–1316. doi:10.1158/1078-0432.CCR-07-1441. ISSN 1078-0432. PMID 18316549. 
  • Pili, R.; Rosenthal, M. A.; Mainwaring, P. N.; Van Hazel, G.; Srinivas, S.; Dreicer, R.; Goel, S.; Leach, J. et al. (2010). “Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC”. Clinical Cancer Research 16 (10): 2906–14. doi:10.1158/1078-0432.CCR-09-3026. PMID 20460477. 
  • Homsi, J.; Simon, G. R.; Garrett, C. R.; Springett, G.; De Conti, R.; Chiappori, A. A.; Munster, P. N.; Burton, M. K. et al. (2007). “Phase I Trial of Poly-L-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies”. Clinical Cancer Research 13 (19): 5855–61. doi:10.1158/1078-0432.CCR-06-2821. PMID 17908979. 
  • Vogel, V. G.; Costantino, JP; Wickerham, DL; Cronin, WM; Cecchini, RS; Atkins, JN; Bevers, TB; Fehrenbacher, L et al. (2006). “Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial”. JAMA 295 (23): 2727–41. doi:10.1001/jama.295.23.joc60074. PMID 16754727. 
  • Kahan, M; Gil, B; Adar, R; Shapiro, E (2008). “Towards Molecular Computers that Operate in a Biological Environment”. Physica D: Nonlinear Phenomena 237 (9): 1165–1172. doi:10.1016/j.physd.2008.01.027. 
  • Andersen, Ebbe S.; Dong, Mingdong; Nielsen, Morten M.; Jahn, Kasper; Subramani, Ramesh; Mamdouh, Wael; Golas, Monika M.; Sander, Bjoern et al. (2009). “Self-assembly of a nanoscale DNA box with a controllable lid”. Nature 459 (7243): 73–6. doi:10.1038/nature07971. PMID 19424153. 

medscape.com

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Muller, R; Keck, C (2004). “Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles”. Journal of Biotechnology 113 (1–3): 151–170. doi:10.1016/j.jbiotec.2004.06.007. PMID 15380654. 
  • Bertrand N, Leroux JC.; Leroux (2011). “The journey of a drug carrier in the body: an anatomo-physiological perspective”. Journal of Controlled Release 161 (2): 152–63. doi:10.1016/j.jconrel.2011.09.098. PMID 22001607. 
  • Scott, Robert C; Crabbe, Deborah; Krynska, Barbara; Ansari, Ramin; Kiani, Mohammad F (2008). “Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue”. Expert Opinion on Drug Delivery 5 (4): 459–70. doi:10.1517/17425247.5.4.459. PMID 18426386. 
  • Noyhouzer, Tomer; L’Homme, Chloé; Beaulieu, Isabelle; Mazurkiewicz, Stephanie; Kuss, Sabine; Kraatz, Heinz-Bernhard; Canesi, Sylvain; Mauzeroll, Janine (2016-05-03). “Ferrocene-Modified Phospholipid: An Innovative Precursor for Redox-Triggered Drug Delivery Vesicles Selective to Cancer Cells”. Langmuir 32 (17): 4169–4178. doi:10.1021/acs.langmuir.6b00511. ISSN 0743-7463. PMID 26987014. 
  • He, X; Bonaparte, N; Kim, S; Acharya, B; Lee, JY; Chi, L; Lee, HJ; Paik, YK et al. (2012). “Enhanced delivery of T cells to tumor after chemotherapy using membrane-anchored, apoptosis-targeted peptide”. Journal of Controlled Release 162 (6): 521–8. doi:10.1016/j.jconrel.2012.07.023. PMID 22824781. 
  • Cobleigh, M; Langmuir, VK; Sledge, GW; Miller, KD; Haney, L; Novotny, WF; Reimann, JD; Vassel, A (2003). “A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer”. Seminars in Oncology 30 (5 Suppl 16): 117–24. doi:10.1053/j.seminoncol.2003.08.013. PMID 14613032. 
  • Seidman, A.; Hudis, C; Pierri, MK; Shak, S; Paton, V; Ashby, M; Murphy, M; Stewart, SJ et al. (2002). “Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience”. Journal of Clinical Oncology 20 (5): 1215–21. doi:10.1200/JCO.20.5.1215. PMID 11870163. 
  • Brufsky, Adam (2009). “Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer”. American Journal of Clinical Oncology 33 (2): 186–95. doi:10.1097/COC.0b013e318191bfb0. PMID 19675448. 
  • Lee, Jinhyun Hannah; Yeo, Yoon (2015-03-24). “Controlled drug release from pharmaceutical nanocarriers”. Chemical Engineering Science 125: 75–84. doi:10.1016/j.ces.2014.08.046. PMC 4322773. PMID 25684779. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322773/. 
  • Cho, Kwangjae; Wang, Xu; Nie, Shuming; Chen, Zhuo Georgia; Shin, Dong M. (2008-03-01). “Therapeutic nanoparticles for drug delivery in cancer”. Clinical Cancer Research 14 (5): 1310–1316. doi:10.1158/1078-0432.CCR-07-1441. ISSN 1078-0432. PMID 18316549. 
  • Pili, R.; Rosenthal, M. A.; Mainwaring, P. N.; Van Hazel, G.; Srinivas, S.; Dreicer, R.; Goel, S.; Leach, J. et al. (2010). “Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC”. Clinical Cancer Research 16 (10): 2906–14. doi:10.1158/1078-0432.CCR-09-3026. PMID 20460477. 
  • Homsi, J.; Simon, G. R.; Garrett, C. R.; Springett, G.; De Conti, R.; Chiappori, A. A.; Munster, P. N.; Burton, M. K. et al. (2007). “Phase I Trial of Poly-L-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies”. Clinical Cancer Research 13 (19): 5855–61. doi:10.1158/1078-0432.CCR-06-2821. PMID 17908979. 
  • Vogel, V. G.; Costantino, JP; Wickerham, DL; Cronin, WM; Cecchini, RS; Atkins, JN; Bevers, TB; Fehrenbacher, L et al. (2006). “Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial”. JAMA 295 (23): 2727–41. doi:10.1001/jama.295.23.joc60074. PMID 16754727. 
  • Andersen, Ebbe S.; Dong, Mingdong; Nielsen, Morten M.; Jahn, Kasper; Subramani, Ramesh; Mamdouh, Wael; Golas, Monika M.; Sander, Bjoern et al. (2009). “Self-assembly of a nanoscale DNA box with a controllable lid”. Nature 459 (7243): 73–6. doi:10.1038/nature07971. PMID 19424153. 

ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

umn.edu

license.umn.edu

  • Macosko, Cristopher W. "Polymer Nanoparticles Improve Delivery of Compounds” University of Minnesota Office for Technology Commercialization.“Nanodelivery”. 2012年3月24日時点のオリジナルよりアーカイブ。2021年1月17日閲覧。

web.archive.org

  • Macosko, Cristopher W. "Polymer Nanoparticles Improve Delivery of Compounds” University of Minnesota Office for Technology Commercialization.“Nanodelivery”. 2012年3月24日時点のオリジナルよりアーカイブ。2021年1月17日閲覧。

worldcat.org

search.worldcat.org

  • Noyhouzer, Tomer; L’Homme, Chloé; Beaulieu, Isabelle; Mazurkiewicz, Stephanie; Kuss, Sabine; Kraatz, Heinz-Bernhard; Canesi, Sylvain; Mauzeroll, Janine (2016-05-03). “Ferrocene-Modified Phospholipid: An Innovative Precursor for Redox-Triggered Drug Delivery Vesicles Selective to Cancer Cells”. Langmuir 32 (17): 4169–4178. doi:10.1021/acs.langmuir.6b00511. ISSN 0743-7463. PMID 26987014. 
  • Cho, Kwangjae; Wang, Xu; Nie, Shuming; Chen, Zhuo Georgia; Shin, Dong M. (2008-03-01). “Therapeutic nanoparticles for drug delivery in cancer”. Clinical Cancer Research 14 (5): 1310–1316. doi:10.1158/1078-0432.CCR-07-1441. ISSN 1078-0432. PMID 18316549.